Episode Description
Listen to the episode on a streaming platform by clicking one of the links below:
This week’s edition offers four predictions about payer mix headwinds, 340B rebates, cybersecurity, and clinical AI.
Prediction #1: The ACA Exchange-driven payer-mix hit will keep deepening through H2 2026, and the for-profits' full-year guidance marks the trajectory the rest of the sector is on.
Our Call: The H2 2026 self-pay and bad-debt hit could land harder than mid-year budgets assume. The question is whether it's in your FY2027 budget or discovered against it.
Prediction #2: By the end of 2026, more drug manufacturers will tie 340B pricing to their own claims-data mandates and enforce by withholding discounts. HRSA will not force a reversal of those policies.
Our Call: Health systems betting on a federal rescue from manufacturers’ claims-data mandates are likely to be disappointed. Regardless of whether it’s a drug manufacturer-led process or federal program, hospitals will end up submitting claims data to access discounts they are statutorily owed.
Prediction #3: The debate over the HIPAA Security Rule is a distraction from a more urgent reality: AI is about to enable vulnerability discovery and cyberattacks at a scale that health systems simply aren't ready for.
Our Call: New AI tools are creating a radically new cybersecurity world. Vulnerability discovery is scaling rapidly, while healthcare remains constrained by its ability to deploy fixes across complex clinical environments. By year-end, the board's cybersecurity question will be, "Of the vulnerabilities we've identified, how quickly can we remediate them? What is the plan for the ones we can't?"
Prediction #4: OpenEvidence will add 3+ health system deployments by year-end while staying ad-supported and selective about which terms it agrees to.
Our Call: Clinicians aren't waiting for those deals. The individual-clinician Business Associate Agreements leave the system holding the liability while the vendor keeps the ad revenue. Every health system should make a deliberate choice: pursue enterprise integration, stand up a governed alternative (e.g., UpToDate, Doximity), or establish formal guardrails for continued use.

About Our Host
Anika Rasheed
Anika is a Senior Analyst on the Strategy Catalyst team.